The cost‐effectiveness of preoperative autologous blood donation for total hip and knee replacement
- 1 July 1993
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 33 (7), 544-551
- https://doi.org/10.1046/j.1537-2995.1993.33793325048.x
Abstract
Although the frequency of preoperative autologous blood donation is increasing dramatically, the economic implications of its use remain largely unexplored. Decision analysis was used to calculate the cost- effectiveness of autologous blood donation for hip and knee replacement. Cost-effectiveness, expressed as cost per quality-adjusted year of life saved, was based on observed red cell use in 629 patients undergoing surgery at two tertiary-care centers. Autologous blood donation for bilateral and revision joint replacement cost $40,000 per quality-adjusted year of life saved at Center 1 and $241,000 at Center 2. Autologous blood donation for primary unilateral hip replacement cost $373,000 per quality-adjusted year of life saved at Center 1 and $740,000 at Center 2. Autologous blood donation was least cost- effective for primary unilateral knee replacement ($1,147,000/quality- adjusted year of life saved at Center 1 and $1,467,000/year at Center 2). Differences between autologous blood collections and transfusion requirements explained variations among procedures in the cost- effectiveness of autologous blood donation. Higher transfusion rates in autologous blood donors than in nondonors accounted for the poorer cost- effectiveness of autologous blood donation at Center 2 than at Center 1. Autologous blood donation is not as cost-effective as most accepted medical practices. Its cost-effectiveness can be improved substantially by the avoidance of overcollection and overtransfusion of autologous blood.Keywords
This publication has 39 references indexed in Scilit:
- Blood transfusion costs: a multicenter studyTransfusion, 1991
- Reports of 355 transfusion‐associated deaths: 1976 through 1985Transfusion, 1990
- Collection and Transfusion of Blood in the United States, 1982–1988New England Journal of Medicine, 1990
- Rapid Development of Myelopathy after HTLV-I Infection Acquired by Transfusion during Cardiac TransplantationNew England Journal of Medicine, 1990
- Exposure of Patients to Human Immunodeficiency Virus through the Transfusion of Blood Components That Test Antibody-NegativeNew England Journal of Medicine, 1989
- Transmission of Retroviruses by Transfusion of Screened Blood in Patients Undergoing Cardiac SurgeryNew England Journal of Medicine, 1989
- Predeposited Autologous Blood for Elective SurgeryNew England Journal of Medicine, 1987
- Reducing the Incidence of Non-A,Non-B Post-Transfusion Hepatitis by Testing Donor Blood for Alanine AminotransferaseNew England Journal of Medicine, 1982
- Predicting Treatment Costs and Life Expectancy for End-Stage Renal DiseaseNew England Journal of Medicine, 1978
- The utility of different health states as perceived by the general publicJournal of Chronic Diseases, 1978